Rajnath Singh and Harshvardhan Launched 2 DG Medicine
Rajnath Singh and Harshvardhan Launched 2 DG Medicine for coronavirus infection made by DRDO.
DRDO has developed medicines for Covid patients released by 2 DG Health Minister and Defense Minister.
Under the first batch of 2 DG (2-deoxy-D-glucose), a new drug of the Defense Research and Development Organization (DRDO) for Corona infected patients,
On Monday, 10,000 doses launched Defense Minister Rajnath Singh and Union Health Minister Harshvardhan. After three trials, its emergency use was approved by DCGI on 1 May 2021.
In the form of powder, this drug will be given in a sachet which will have to be dissolved in water. It is capable of stopping the growth of the virus by visiting infected cells.
Information about this was given in a tweet posted by the Defense Minister’s office.
It has been reported that the first consignment of this medicine will be released by the Defense Minister through video conferencing at 10.30 am today.
The drug has been developed by DRDO’s Nuclear Medicine Institute and Allied Sciences (INMAS) in collaboration with Doctor Reddy Lab.
Last Friday, leading media agency was informed by the DRDO officer that the first batch of 1000 doses of 2DG drug would be released next week and it could be given to Covid patients.
DRDO officials also pointed out, ‘The drug manufacturers are working on speeding up the production process for further use. DRDO scientists, including Dr. Anant Narayan Bhatt, have contributed to the making of this drug. ‘
A clinical trial of this drug has been done and the results have been positive. The trial revealed that these molecules help in the rapid recovery of hospitalized patients and reduce dependence on excess oxygen.
At the request of Prime Minister Narendra Modi for preparations against the epidemic, the DRDO had decided to develop this drug.
In April 2020, during the first wave of the pandemic, INMAS-DRDO scientists started working together with the help of CCMB (Center for Cellular and Molecular Biology), Hyderabad.
It was found that these molecules are effective on the SARS-CoV-2 virus and Are able to stop the increase. Based on these results, DCGI allowed its Phase 2 clinical trial in May 2020.
The second phase of the trial lasted from May to October last year and it yielded very good results.
The trial was conducted in two parts, in the first time 6 hospitals were covered, and in the second time, 11 hospitals of the country were covered.
In this, this drug was given to 110 patients and its effective results came out. In view of this, DCGI also allowed a third clinical trial which was carried out in 27 hospitals from December 2020 to March 2021 on 220 patients.
These hospitals are in Delhi, Uttar Pradesh, West Bengal, Gujarat, Rajasthan, Maharashtra, Andhra Pradesh, Telangana, Karnataka, and Tamil Nadu.
